This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
sclerostin
Sclerostin
Sclerostin (SOST, chr17q21.31) is an osteocyte-secreted Wnt antagonist; binds LRP5/LRP6 → blocks Wnt/β-catenin → inhibits osteoblast bone formation; romosozumab (anti-sclerostin) has dual anabolic+antiresorptive action: 73% RRR vertebral fractures (FRAME trial).
Entry Metadata
| Field | Value |
|---|---|
| ID | sclerostin |
| Name | Sclerostin |
| Status | draft |
| Last reviewed | 2026-06-07 |
| Atlas | 01-human |
| Scale | 03-molecular |
Cross-Atlas Connections
Sources
- Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005;280(20):19883-19887. · PubMed 15778503
- Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532-1543. · PubMed 27641143
- Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417-1427. · PubMed 28892457